Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting
ConclusionsThe HMGA2 test is estimated to improve leukemia-free survival and overall survival outcomes, and yield costs savings from a healthcare system and societal perspective.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Canada Health | Economics | Genetics | Health Management | Leukemia | Study